Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.

ACS chemical neuroscience - 17 Feb 2016

Shen Sida, Benoy Veronick, Bergman Joel A, Kalin Jay H, Frojuello Mariana, Vistoli Giulio, Haeck Wanda, Van Den Bosch Ludo, Kozikowski Alan P

Abstract excerpt

Charcot-Marie-Tooth (CMT) disease is a disorder of the peripheral nervous system where progressive degeneration of motor and sensory nerves leads to motor problems and sensory loss and for which no pharmacological treatment is available. Recently, it has been shown in a model for the axonal form of CMT that histone deacetylase 6 (HDAC6) can serve as a target for the development of a pharmacological therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Charcot-Marie-Tooth Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ganglia, Spinal

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Interleukin-2

Share to Neuroblastoma

Share to Tubulin

Source

Open in PubMed Open full text

Identifiers

PMID: 26599234
DOI: 10.1021/acschemneuro.5b00286
PMCID: PMC4775085

Genes

HDAC6
HDAC1
HSPB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.PMID 26599234Read ↗

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.Semantic proximity Read ↗

Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 InhibitorSemantic proximity Read ↗

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.Semantic proximity Read ↗

HDAC6 α-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseasesSemantic proximity Read ↗

HDAC6 as a potential therapeutic target for peripheral nerve disordersSemantic proximity Read ↗

Charcot-Marie-Tooth disease: emerging mechanisms and therapies.Semantic proximity Read ↗

Treatment of Charcot-Marie-Tooth neuropathies.Semantic proximity Read ↗

HDAC6 Inhibition Corrects Electrophysiological and Axonal Transport Deficits in a Human Stem Cell‐Based Model of Charcot‐Marie‐Tooth Disease (Type 2D)Semantic proximity Read ↗

Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy.Semantic proximity Read ↗

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Semantic proximity Read ↗

HDAC6 inhibition partially alleviates mitochondrial trafficking defects and restores motor function in human motor neuron and zebrafish models of Charcot-Marie-Tooth Disease Type 2ASemantic proximity Read ↗

HDAC6 inhibition as a mechanism to prevent neurodegeneration in the mSOD1G93A mouse model of ALSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.